世界の異染性白質ジストロフィー（MLD）治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Metachromatic Leukodystrophy (MLD) Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A14479 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、87ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、異染性白質ジストロフィー（MLD）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。異染性白質ジストロフィー（MLD）治療の種類別市場規模（AGT-183、DUOC-01、GSK-2696274、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・異染性白質ジストロフィー（MLD）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：ArmaGen Inc、GlaxoSmithKline Plc、Recursion Pharmaceuticals Inc、RegenxBio Inc、Takeda ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：AGT-183、DUOC-01、GSK-2696274、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・異染性白質ジストロフィー（MLD）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・異染性白質ジストロフィー（MLD）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・異染性白質ジストロフィー（MLD）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・異染性白質ジストロフィー（MLD）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・異染性白質ジストロフィー（MLD）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Metachromatic Leukodystrophy (MLD) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Metachromatic Leukodystrophy (MLD) Treatment size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Metachromatic Leukodystrophy (MLD) Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Metachromatic Leukodystrophy (MLD) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
AGT-183
DUOC-01
GSK-2696274
Others

Market segment by Application can be divided into
Hospital
Clinic
Others

The key market players for global Metachromatic Leukodystrophy (MLD) Treatment market are listed below:
ArmaGen Inc
GlaxoSmithKline Plc
Recursion Pharmaceuticals Inc
RegenxBio Inc
Takeda

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Metachromatic Leukodystrophy (MLD) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, with price, sales, revenue and global market share of Metachromatic Leukodystrophy (MLD) Treatment from 2019 to 2021.
Chapter 3, the Metachromatic Leukodystrophy (MLD) Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Metachromatic Leukodystrophy (MLD) Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Metachromatic Leukodystrophy (MLD) Treatment market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Metachromatic Leukodystrophy (MLD) Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Metachromatic Leukodystrophy (MLD) Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 AGT-183
1.2.3 DUOC-01
1.2.4 GSK-2696274
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size & Forecast
1.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Value (2016-2026))
1.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume (2016-2026)
1.4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Metachromatic Leukodystrophy (MLD) Treatment Production Capacity Analysis
1.5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Total Production Capacity (2016-2026)
1.5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
1.6.2 Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
1.6.3 Metachromatic Leukodystrophy (MLD) Treatment Trends Analysis
2 Manufacturers Profiles
2.1 ArmaGen Inc
2.1.1 ArmaGen Inc Details
2.1.2 ArmaGen Inc Major Business
2.1.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
2.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 GlaxoSmithKline Plc
2.2.1 GlaxoSmithKline Plc Details
2.2.2 GlaxoSmithKline Plc Major Business
2.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
2.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Recursion Pharmaceuticals Inc
2.3.1 Recursion Pharmaceuticals Inc Details
2.3.2 Recursion Pharmaceuticals Inc Major Business
2.3.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
2.3.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 RegenxBio Inc
2.4.1 RegenxBio Inc Details
2.4.2 RegenxBio Inc Major Business
2.4.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
2.4.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Takeda
2.5.1 Takeda Details
2.5.2 Takeda Major Business
2.5.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product and Services
2.5.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturer
3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Metachromatic Leukodystrophy (MLD) Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Metachromatic Leukodystrophy (MLD) Treatment Manufacturer Market Share
3.4.2 Top 6 Metachromatic Leukodystrophy (MLD) Treatment Manufacturer Market Share
3.5 Global Metachromatic Leukodystrophy (MLD) Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Metachromatic Leukodystrophy (MLD) Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region
4.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2016-2026)
4.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026)
4.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026)
4.4 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026)
4.5 South America Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026)
4.6 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Type (2016-2026)
5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2016-2026)
5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Application (2016-2026)
6.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2016-2026)
6.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2026)
7.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2026)
7.3 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
7.3.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2026)
8.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2026)
8.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
8.3.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region
9.3.1 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2026)
10.2 South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2026)
10.3 South America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
10.3.1 South America Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
11.3.1 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Metachromatic Leukodystrophy (MLD) Treatment Typical Distributors
12.3 Metachromatic Leukodystrophy (MLD) Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. ArmaGen Inc Basic Information, Manufacturing Base and Competitors
Table 4. ArmaGen Inc Major Business
Table 5. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
Table 6. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Plc Major Business
Table 9. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
Table 10. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Recursion Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 12. Recursion Pharmaceuticals Inc Major Business
Table 13. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
Table 14. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. RegenxBio Inc Basic Information, Manufacturing Base and Competitors
Table 16. RegenxBio Inc Major Business
Table 17. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product and Services
Table 18. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Takeda Basic Information, Manufacturing Base and Competitors
Table 20. Takeda Major Business
Table 21. Takeda Metachromatic Leukodystrophy (MLD) Treatment Product and Services
Table 22. Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 24. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 25. Market Position of Manufacturers in Metachromatic Leukodystrophy (MLD) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 26. Global Metachromatic Leukodystrophy (MLD) Treatment Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 27. Head Office and Metachromatic Leukodystrophy (MLD) Treatment Production Site of Key Manufacturer
Table 28. Metachromatic Leukodystrophy (MLD) Treatment New Entrant and Capacity Expansion Plans
Table 29. Metachromatic Leukodystrophy (MLD) Treatment Mergers & Acquisitions in the Past Five Years
Table 30. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2016-2021e) & (K Pcs)
Table 31. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026) & (K Pcs)
Table 32. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 33. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 34. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 35. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (K Pcs)
Table 36. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 37. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 38. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2016-2021e) & (USD/Pcs)
Table 39. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2026) & (USD/Pcs)
Table 40. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 41. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (K Pcs)
Table 42. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 43. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 44. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2016-2021e) & (USD/Pcs)
Table 45. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2026) & (USD/Pcs)
Table 46. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 47. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (K Pcs)
Table 48. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 49. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 50. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 51. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (K Pcs)
Table 52. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 53. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (K Pcs)
Table 54. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 55. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (K Pcs)
Table 56. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 57. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 58. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 59. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (K Pcs)
Table 60. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 61. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (K Pcs)
Table 62. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2016-2021e) & (K Pcs)
Table 63. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026) & (K Pcs)
Table 64. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 65. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 66. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 67. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (K Pcs)
Table 68. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 69. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (K Pcs)
Table 70. South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 71. South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (K Pcs)
Table 72. South America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 73. South America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 74. South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 75. South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (K Pcs)
Table 76. South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 77. South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (K Pcs)
Table 78. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 79. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (K Pcs)
Table 80. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 81. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 82. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 83. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (K Pcs)
Table 84. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 85. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (K Pcs)
Table 86. Direct Channel Pros & Cons
Table 87. Indirect Channel Pros & Cons
Table 88. Metachromatic Leukodystrophy (MLD) Treatment Typical Distributors
Table 89. Metachromatic Leukodystrophy (MLD) Treatment Typical Customers
List of Figures
Figure 1. Metachromatic Leukodystrophy (MLD) Treatment Picture
Figure 2. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type in 2020
Figure 3. AGT-183
Figure 4. DUOC-01
Figure 5. GSK-2696274
Figure 6. Others
Figure 7. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application in 2020
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 12. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (2016-2026) & (K Pcs)
Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2016-2026) & (USD/Pcs)
Figure 15. Global Metachromatic Leukodystrophy (MLD) Treatment Production Capacity (2016-2026) & (K Pcs)
Figure 16. Global Metachromatic Leukodystrophy (MLD) Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 17. Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
Figure 18. Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
Figure 19. Metachromatic Leukodystrophy (MLD) Treatment Market Trends
Figure 20. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturer in 2020
Figure 21. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Manufacturer in 2020
Figure 22. Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. Top 3 Metachromatic Leukodystrophy (MLD) Treatment Manufacturer (Revenue) Market Share in 2020
Figure 24. Top 6 Metachromatic Leukodystrophy (MLD) Treatment Manufacturer (Revenue) Market Share in 2020
Figure 25. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2016-2026)
Figure 26. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2016-2026)
Figure 27. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026) & (USD Million)
Figure 28. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026) & (USD Million)
Figure 29. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026) & (USD Million)
Figure 30. South America Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026) & (USD Million)
Figure 31. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue (2016-2026) & (USD Million)
Figure 32. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2016-2026)
Figure 33. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2016-2026)
Figure 34. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2016-2026) & (USD/Pcs)
Figure 35. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2016-2026)
Figure 36. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2016-2026)
Figure 37. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2016-2026) & (USD/Pcs)
Figure 38. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2016-2026)
Figure 39. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2016-2026)
Figure 40. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2016-2026)
Figure 41. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2016-2026)
Figure 42. United States Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2016-2026)
Figure 46. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2016-2026)
Figure 47. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2016-2026)
Figure 48. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2016-2026)
Figure 49. Germany Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2016-2026)
Figure 58. China Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Korea Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2016-2026)
Figure 65. South America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2016-2026)
Figure 66. South America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2016-2026)
Figure 67. South America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2016-2026)
Figure 71. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Egypt Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

---